NCT04938609View on ClinicalTrials.gov

Neoadjuvant Immunoradiotherapy in Head & Neck Cancer (NIRT 2-HNC)

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

January 11, 2022

Primary Completion Date

January 11, 2027

Study Completion Date

January 11, 2031

Conditions
Head and Neck CancerHead and Neck Squamous Cell Carcinoma
Interventions
DRUG

Pembrolizumab

Pembrolizumab is a humanized anti-PD-1 mAb of the IgG4/kappa isotype with a stabilizing S228P sequence alteration in the Fc region.

RADIATION

Stereotactic Body Radiation Therapy (5 days)

8Gy x 3 (Mon-Fri) GTV+3mm

PROCEDURE

Surgical Resection

Surgical Resection of Tumor

Trial Locations (3)

92037

University of San Diego, San Diego

97213

Portland Providence Medical Center, Portland

97225

Providence St. Vincent Medical Center, Portland

All Listed Sponsors
collaborator

Providence Cancer Center, Earle A. Chiles Research Institute

OTHER

lead

Providence Health & Services

OTHER